Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yung, Chee Fu ^a,b   Andrews, Nick ^b   Hoschler, Katja ^b   Miller, Elizabeth ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS VACCINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; MALE; SCHOOL CHILD; SEROCONVERSION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PREGNANCY; YOUNG ADULT;

EID: 84874343234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056844     Document Type: Article

References (26)

1. Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, et al. (2011) Risk Factors for Severe Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled Analysis. PLoS Med 8(7): e1001053 doi:10.1371/journal.pmed.1001053.
2. Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ Vaccination against pandemic influenza A/H1N1v in England: a real-time economic Evaluation Vaccine. 2010 Mar 11;28(12): 2370-84. Epub 2010 Jan 21.).
3. Beyer WE, Palache AM, Sprenger MJ, Hendriksen E, Tukker JJ, et al. (1996) "Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults." Vaccine. 14 (14) (): 1331-39.
4. Andrews NJ, Walker WT, Finn A, Heath PT, Collinson AC, et al. (2011) Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine. Oct 19 29(45): 7913-9.
5. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P, (2010) AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clinical Infectious Diseases 51: 668-77.
6. Andrews N, Waight P, Yung CF, Miller L, (2011) Age specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis. Jan 1 203(1): 32-9.
7. Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, et al. (2011) Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill 2011;16:pii,19763.
8. CMO letter-The H1N1 swine flu vaccination programme 2009-2010. Available: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/dh/en/documents/digitalasset/dh_107190.pdf. Accessed 11 September 2012.
9. CMO letter announcing amendment of Pandemrix® license to allow a one-dose schedule in children. Available: http://www.nelm.nhs.uk/en/NeLM-Area/News/2009-December/16/CMO-letter-announcing-amendment-of-Pandemrix-license-to-allow-a-one-dose-schedule-in-children-/. Accessed 11 September 2012.
10. Emborg HD, Krause TG, Hviid A, Simonsen J, Mølbak K, (2011) Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ. Jan 25 344: d7901 doi:10.1136/bmj.d7901.
11. Summary Product Charateristic of Pandemrix™. Available: http://www.medicines.org.uk/emc/medicine/22352/SPC/Pandemrixsuspensionandemulsionforemulsionforinjection/. Accessed 11 September 2012.
12. EMeA CPMP- Note for guidance on harmonisation of requirements for influenza vaccines. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf. Accessed 11 September 2012.
13. Peetersa M, Regnerb S, Vamanc T, Devastera JM, Peeter LR (2012) Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials; Vaccine Volume 30, Issue 45, 5 October, Pages 6483-6491.
14. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M, (2010) Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomized controlled phase 2 trials. Lancet 375: 41-8.
15. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, et al. (2010) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children. JAMA 303: 37-46.
16. Huijskens E, Rossen J, Mulder P, van Beek R, van Vugt H, et al. (2011) Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol. Sep;18(9): 1401-5. Epub 2011 Jul 27.
17. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R, (2010) Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. Mar 8 10: 18.
18. Nauta JJ, Beyer WE, Osterhaus AD, (2009) On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals;37(August (4)): 216-21.
19. Khurana S, Verma N, Talaat KR, Karron RA, Golding H (2012) Immune Response Following H1N1pdm09 Vaccination: Differences in Antibody Repertoire and Avidity in Young Adults and Elderly Populations Stratified by Age and Gender. J Infect Dis. Feb;205(4): 610-20. Epub 2011 Dec 29.
20. Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, et al. (2012) Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. Int J Infect Dis. Aug 16(8): e621-7.
21. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.Nat Med. Jan 29 18(2): 274-80.
22. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M, (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 375 (9720) (): 1100-08.
23. HPA. Available: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/EpidemiologicalData/15influsInfluenzavaccinationuptakemonitoring/#r1. Accessed 11 September 2012.
24. Potter CW, Oxford JS, (1979) Determinants of immunity to influenza infection in man. Br Med Bull 35: 69-75.
25. Hobson D, Curry RL, Beare AS, Ward-Gardner A, (1972) The role of serum Haemagglutination-Inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70: 767-777.
26. De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD, (2003) Haemagglutination-inhibiting antibody to influenza virus; Dev Biol (Basel). 115: 63-73.